TY - JOUR
T1 - Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study
AU - Fonnes, T.
AU - Trovik, J.
AU - Edqvist, P. H. D.
AU - Fasmer, K. E.
AU - Marcickiewicz, J.
AU - Tingulstad, S.
AU - Staff, A. C.
AU - Bjørge, L.
AU - Amant, F.
AU - Haldorsen, I. S.
AU - Werner, H. M. J.
AU - Akslen, L. A.
AU - Tangen, I. L.
AU - Krakstad, C.
PY - 2018
Y1 - 2018
N2 - Objective: Correct preoperative identification of high-risk patients is important to optimise surgical treatment and improve survival. We wanted to explore if asparaginase-like protein 1 (ASRGL1) expression in curettage could predict lymph node metastases and poor outcome, potentially improving preoperative risk stratification. Design: Multicentre study. Setting: Ten hospitals in Norway, Sweden and Belgium. Population: Women diagnosed with endometrial carcinoma. Methods: ASRGL1 expression in curettage specimens from 1144 women was determined by immunohistochemistry. Main outcome measures: ASRGL1 status related to disease-specific survival, lymph node status, preoperative imaging parameters and clinicopathological data. Results: ASRGL1 expression had independent prognostic value in multivariate survival analyses, both in the whole patient population (hazard ratio (HR) 1.63, 95% CI 1.11–2.37, P = 0.012) and in the low-risk curettage histology subgroup (HR 2.54, 95% CI 1.44–4.47, P = 0.001). Lymph node metastases were more frequent in women with low expression of ASRGL1 compared with women with high ASRGL1 levels (23% versus 10%, P < 0.001), and low ASRGL1 level was found to independently predict lymph node metastases (odds ratio 2.07, 95% CI 1.27–3.38, P = 0.003). Conclusions: Low expression of ASRGL1 in curettage independently predicts lymph node metastases and poor disease-specific survival. Tweetable abstract: Low ASRGL1 expression in curettage predicts lymph node metastasis and poor survival in endometrial carcinoma.
AB - Objective: Correct preoperative identification of high-risk patients is important to optimise surgical treatment and improve survival. We wanted to explore if asparaginase-like protein 1 (ASRGL1) expression in curettage could predict lymph node metastases and poor outcome, potentially improving preoperative risk stratification. Design: Multicentre study. Setting: Ten hospitals in Norway, Sweden and Belgium. Population: Women diagnosed with endometrial carcinoma. Methods: ASRGL1 expression in curettage specimens from 1144 women was determined by immunohistochemistry. Main outcome measures: ASRGL1 status related to disease-specific survival, lymph node status, preoperative imaging parameters and clinicopathological data. Results: ASRGL1 expression had independent prognostic value in multivariate survival analyses, both in the whole patient population (hazard ratio (HR) 1.63, 95% CI 1.11–2.37, P = 0.012) and in the low-risk curettage histology subgroup (HR 2.54, 95% CI 1.44–4.47, P = 0.001). Lymph node metastases were more frequent in women with low expression of ASRGL1 compared with women with high ASRGL1 levels (23% versus 10%, P < 0.001), and low ASRGL1 level was found to independently predict lymph node metastases (odds ratio 2.07, 95% CI 1.27–3.38, P = 0.003). Conclusions: Low expression of ASRGL1 in curettage independently predicts lymph node metastases and poor disease-specific survival. Tweetable abstract: Low ASRGL1 expression in curettage predicts lymph node metastasis and poor survival in endometrial carcinoma.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85052660801&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29989298
U2 - https://doi.org/10.1111/1471-0528.15403
DO - https://doi.org/10.1111/1471-0528.15403
M3 - Article
C2 - 29989298
SN - 1470-0328
VL - 125
SP - 1695
EP - 1703
JO - BJOG
JF - BJOG
IS - 13
ER -